Part the Cloud: Translational Research Funding for Alzheimer's Disease (PTC)

Funding Agency:
Alzheimers Association

In its seventh iteration, the Alzheimer's Association is pleased to announce the Part the Cloud Translational Research Funding initiative to increase the research efforts in Phase I and Phase II (Proof of Concept) clinical trials directed towards Alzheimer's disease and related dementias internationally.

Applications will be accepted from academic investigators and small companies with lead candidate therapeutic agents that require early stage testing prior to Proof of Concept (POC) Phase 2 or 3 efficacy studies, or with lead therapeutic agents that have already established human safety data and require a small-scale pilot Proof of Mechanism (POM) study to begin proving the scientific concept in humans. This award will support Phase 1 studies or pilot smallscale Phase 2a studies for repurposed drugs in normal individuals or individuals with preclinical or symptomatic Alzheimer's disease (i.e. early human studies to set the stage for efficacy studies), including single and multiple dose studies to establish safety, brain penetration and/or target engagement and POM in preparation for larger proof of concept trials. Both non-profit and small for-profit agencies are eligible.


  • Required Letter of Intent: May 23, 2019
  • Application:  July 31, 2019

Agency Website



Amount Description

Each Part the Cloud Research grant is limited to $750,000 (direct and indirect costs) over two to three years. Requests in any given year may not exceed $500,000 (direct and indirect costs). Indirect costs are capped at 10 percent (rent for laboratory/office space is expected to be covered by indirect costs paid to the institution).

Funding Type





Medical - Translational

External Deadline

May 23, 2019